施维雅集团2024-2025财年销售收入69亿欧元，同比增长16.2%

Core Insights - The core viewpoint of the article highlights the strong financial performance of the SIVIA Group for the fiscal year 2024-2025, driven primarily by its oncology business and significant growth in the U.S. market [1] Financial Performance - The group achieved a sales revenue of €6.9 billion, representing a year-on-year increase of 16.2% [1] - The oncology segment emerged as the main growth driver, generating sales of €2.21 billion, which is a remarkable year-on-year growth of 54.6% [1] - The cardiovascular and venous disease sectors showed stable performance, with sales increasing by 1.8% to reach €2.968 billion [1] Market Breakdown - Revenue from the EU market accounted for 40.5% of the group's total revenue, reflecting a growth of 9.2% compared to the previous fiscal year [1] - The U.S. subsidiary reported revenue of €1.496 billion for the fiscal year 2024-2025, marking a substantial increase of 70.3% from €879 million in the previous fiscal year [1]